Investors

Corporate Profile

Inventiva (Euronext Paris and Nasdaq: IVA) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs.

Regulated Information

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants July 9, 2026
Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders July 8, 2026
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026 July 2, 2026

Presentations

2024 Full-Year Results March 26, 2025
2025 Full-Year Results March 30, 2026

All Presentations

Investor Contacts

IR@inventivapharma.com